Company intelligence / Profile preview

RGCM

Baar, Zug, Switzerland

Ownership: Private
Employees: ~50
Development stage: Other

Overview

RGCC (Research Genetic Cancer Centre) is a global biotechnology company specializing in personalized oncology and advanced genetic testing. The company focuses on the detection and analysis of circulating tumor cells (CTCs) and cancer stem cells (CSCs) to provide comprehensive insights into a patient's cancer profile. Their proprietary liquid biopsy tests, such as Oncotrace and Onconomics, allow for the monitoring of disease progression and the assessment of treatment efficacy for chemotherapy, targeted therapies, and natural substances. RGCC's mission is to empower clinicians and patients with personalized data to optimize cancer management and improve clinical outcomes.

Therapeutic areas: Oncology
Modalities: Diagnostic testLiquid biopsyCell analysis
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on RGCM.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RGCM.

Explore the full profile